The role of microRNA in the pathogenesis of glial brain tumors
- PMID: 35330864
- PMCID: PMC8907600
- DOI: 10.1016/j.ncrna.2022.02.005
The role of microRNA in the pathogenesis of glial brain tumors
Abstract
Gliomas are the most common and fatal primary brain tumor in adults. Gliomas are highly invasive tumors with the highest mortality among all primary malignant brain tumors. Until now, the molecular mechanism that is responsible for glioma tumorigenesis and progression remains unclear. MicroRNAs (miRNAs) are short non-coding RNAs with 18-22 nucleotides in length which function as key regulators of various biological processes through negative control over gene expression at the post-transcriptional level. MiRNA dysregulation plays a key role in cancer oncogenesis, including the development and progression of gliomas. MiRNAs regulate a wide range of tumor processes including cell proliferation, differentiation, angiogenesis, invasion and apoptosis. In addition, microRNAs can be selectively packaged, secreted, and transported between cells in exosomes that are able to cross the blood-brain barrier (BBB) and are readily available in almost all types of human body fluids, making them promising biomarkers for gliomas. Increasing evidence has shown that miRNAs play an important role in glioma. For example, a large number studies indicated that this miRNA-21could affect on a variety of cellular and molecular pathways such as insulin-like growth factor (IGF)-binding protein-3 (IGFBP3), RECK, and TIMP3. Exosomal miR-21 may has key roles in gliomas pathogenesis. These findings indicated that miR-21 has critical roles in gliomas pathogenesis and could be used as diagnostic and therapeutic biomarkers for glioma patients. Profiling miRNAs expression in various human pathological conditions is a rapidly growing field, and it is likely that the knowledge gained from these studies regarding the genesis of gliomas will have the potential in the field of minimally invasive therapy with miRNA to improve the prognosis of patients with this pathology.
Keywords: Expression; Glioblastoma; Glioma; Pathogenesis; Therapy; miRNA.
© 2022 The Authors.
Conflict of interest statement
The authors declare they have no conflict of interest.
Similar articles
-
Recent insights into the microRNA-dependent modulation of gliomas from pathogenesis to diagnosis and treatment.Cell Mol Biol Lett. 2022 Aug 3;27(1):65. doi: 10.1186/s11658-022-00354-4. Cell Mol Biol Lett. 2022. PMID: 35922753 Free PMC article. Review.
-
Role of exosomes in malignant glioma: microRNAs and proteins in pathogenesis and diagnosis.Cell Commun Signal. 2020 Aug 3;18(1):120. doi: 10.1186/s12964-020-00623-9. Cell Commun Signal. 2020. PMID: 32746854 Free PMC article. Review.
-
MiR-21: A key player in glioblastoma pathogenesis.J Cell Biochem. 2018 Feb;119(2):1285-1290. doi: 10.1002/jcb.26300. Epub 2017 Aug 28. J Cell Biochem. 2018. PMID: 28727188 Review.
-
miRNA Regulation in Gliomas: Usual Suspects in Glial Tumorigenesis and Evolving Clinical Applications.J Neuropathol Exp Neurol. 2017 Apr 1;76(4):246-254. doi: 10.1093/jnen/nlx005. J Neuropathol Exp Neurol. 2017. PMID: 28431179 Review.
-
A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas.J Exp Clin Cancer Res. 2016 Jul 30;35(1):124. doi: 10.1186/s13046-016-0393-0. J Exp Clin Cancer Res. 2016. PMID: 27476114 Free PMC article.
Cited by
-
Subependymal Giant Cell Astrocytoma: The Molecular Landscape and Treatment Advances.Cancers (Basel). 2024 Oct 7;16(19):3406. doi: 10.3390/cancers16193406. Cancers (Basel). 2024. PMID: 39410026 Free PMC article. Review.
-
MiRNA regulated therapeutic potential of the stromal vascular fraction: Current clinical applications - A systematic review.Noncoding RNA Res. 2022 Dec 19;8(2):146-154. doi: 10.1016/j.ncrna.2022.12.003. eCollection 2023 Jun. Noncoding RNA Res. 2022. PMID: 36632616 Free PMC article. Review.
-
Circular RNAs as biomarkers for lung cancer.Noncoding RNA Res. 2022 Nov 7;8(1):83-88. doi: 10.1016/j.ncrna.2022.11.002. eCollection 2023 Mar. Noncoding RNA Res. 2022. PMID: 36407660 Free PMC article. Review.
-
ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression.Int J Mol Sci. 2023 Apr 22;24(9):7703. doi: 10.3390/ijms24097703. Int J Mol Sci. 2023. PMID: 37175410 Free PMC article.
-
Natural compounds as regulators of miRNAs: exploring a new avenue for treating brain cancer.Naunyn Schmiedebergs Arch Pharmacol. 2025 Aug;398(8):9551-9568. doi: 10.1007/s00210-025-03934-1. Epub 2025 Mar 6. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40047858 Review.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous